Emily M. Leproust Sells 2,802 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 2,802 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $83,359.50. Following the sale, the chief executive officer now owns 649,630 shares in the company, valued at $19,326,492.50. This trade represents a 0.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Twist Bioscience Stock Down 3.7%

TWST stock traded down $1.08 during midday trading on Wednesday, reaching $28.33. The company had a trading volume of 1,142,745 shares, compared to its average volume of 978,754. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 1 year low of $27.12 and a 1 year high of $60.90. The company has a 50 day moving average of $35.90 and a two-hundred day moving average of $42.50. The company has a market capitalization of $1.70 billion, a P/E ratio of -8.38 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. On average, equities research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio bought a new position in Twist Bioscience during the first quarter worth $711,000. Intech Investment Management LLC grew its holdings in shares of Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Bayforest Capital Ltd raised its stake in shares of Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock worth $191,000 after acquiring an additional 1,604 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after buying an additional 1,588,587 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock worth $36,629,000 after purchasing an additional 37,577 shares during the period.

Analyst Ratings Changes

A number of brokerages have issued reports on TWST. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Guggenheim reissued a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Robert W. Baird dropped their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Barclays reduced their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.